<p>Serious adverse events in patients who completed all pharmacokinetic assessments (N = 25) and in patients who did not complete the assessments (N = 8).</p
Adverse events (according to low-level term) reported in at least 10 patients during follow-up.</p
<p>Relative risks (RRs) of grade 3–4 adverse events for patients who received BP in addition to stan...
<p>Treatment-emergent adverse events experienced by ≥3 patients in any treatment group in the Phase ...
<p>Number and percentages of subjects showing adverse events after administration of drugs in differ...
<p>N, number of patients; n, number of events; %, percentage based on N = 275.</p
Adverse drug reactions and laboratory abnormalities reported in patients with ≥ 5 events (n = 1,293)...
The occurrence of adverse events after receiving the first and second dose in the participants with ...
The occurrence of adverse events after receiving the first and second dose in the participants with ...
<p>Treatment-emergent adverse events experienced by ≥5% of patients in either treatment group (treat...
<p>Serious adverse events (SAE) in patients while using methotrexate (first and later courses).</p
<p>Number of patients experiencing minor and major adverse events per study arm (related to ciclospo...
<p>AE, adverse event; DLT, dose-limiting toxicity (DLTs were defined as grade ≥3 infusion-related ne...
Treatment-related adverse events occurring in ≥1% of the total population (SS).</p
<p>Occurrence of adverse events in patients grouped by ITPase activity, percentage of adverse events...
Drug-related problems, including adverse drug reactions (ADRs), contribute to a significant health- ...
Adverse events (according to low-level term) reported in at least 10 patients during follow-up.</p
<p>Relative risks (RRs) of grade 3–4 adverse events for patients who received BP in addition to stan...
<p>Treatment-emergent adverse events experienced by ≥3 patients in any treatment group in the Phase ...
<p>Number and percentages of subjects showing adverse events after administration of drugs in differ...
<p>N, number of patients; n, number of events; %, percentage based on N = 275.</p
Adverse drug reactions and laboratory abnormalities reported in patients with ≥ 5 events (n = 1,293)...
The occurrence of adverse events after receiving the first and second dose in the participants with ...
The occurrence of adverse events after receiving the first and second dose in the participants with ...
<p>Treatment-emergent adverse events experienced by ≥5% of patients in either treatment group (treat...
<p>Serious adverse events (SAE) in patients while using methotrexate (first and later courses).</p
<p>Number of patients experiencing minor and major adverse events per study arm (related to ciclospo...
<p>AE, adverse event; DLT, dose-limiting toxicity (DLTs were defined as grade ≥3 infusion-related ne...
Treatment-related adverse events occurring in ≥1% of the total population (SS).</p
<p>Occurrence of adverse events in patients grouped by ITPase activity, percentage of adverse events...
Drug-related problems, including adverse drug reactions (ADRs), contribute to a significant health- ...
Adverse events (according to low-level term) reported in at least 10 patients during follow-up.</p
<p>Relative risks (RRs) of grade 3–4 adverse events for patients who received BP in addition to stan...
<p>Treatment-emergent adverse events experienced by ≥3 patients in any treatment group in the Phase ...